SC
CNTA

Shay Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Shay Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,269
Closed -$234K – 345
2025
Q1 		$234K Buy
16,269
+2,000
+14% +$32.7K 0.03% 226
2024
Q4 		$239K Buy
+14,269
New +$236K 0.04% 242

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Shay Capital's CNTA Position: Q2 2025 in Review

Shay Capital sold out of Centessa Pharmaceuticals (CNTA) in Q2 2025, closing a stake of 16,269 shares — an estimated $234K sold.

Shay Capital first reported a position in CNTA in Q4 2024 and held it in 2 quarters. The position peaked at $239K in Q4 2024. 117 funds tracked by Wall St. Rank hold CNTA as of Q2 2025.

  • Shay Capital reported no remaining Centessa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Shay Capital sold 16,269 Centessa Pharmaceuticals shares in Q2 2025, an estimated $234K.
  • Shay Capital first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Shay Capital's Centessa Pharmaceuticals position peaked at $239K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2025.

Based on Shay Capital's 13F filing for Q2 2025, filed 14 Aug 2025.